Copium is a hell of a drug.

---

They should just legalize all drug dealing and prostitution. Might give me a reason to work out more so that Timmy or Peter could choose me.

---

Shit, probably. I did some work there about 15 years ago and they were doing really advanced stuff back then, eg massive HPC/ML clusters doing drug discovery work, protein folding, etc. It's the only place I've met dudes with computer science phds.

---

Drug compounding specifically (see chain above)

---

"We are surprised by the (U.S. Food & Drug Administration's) feedback, which is a drastic change from the guidance the FDA provided in November 2024," said Matt Kapusta, UniQure's CEO. UniQure said it plans to urgently interact with the FDA to find a path forward for the timely accelerated approval of AMT-130.

---

wow, they seem to also have fired the head of the Food and Drug Administration's drug division (https://www.nytimes.com/2025/11/02/health/fda-drug-unit-chief.html)

---

I have a few theories. Now, keep in mind, many people aren't supposed to take Tylenol because the active ingredient is really hard on your liver. If Kennedy has any sort of a drinking problem, then his doctor has probably brought this up. There was also already something of a movement to get said active ingredient a higher rating. So with that in mind, I think Tylenol was an easy drug to go after. And if there was a thought they could make some money off of it, then it explains why they went after Tylenol specifically when acetaminophen is in a lot of different drugs

---

True. They dress more expensively, like wannabe columbian drug dealers, but the Mormons have that timeless class. 😮‍💨👌

---

$ALT looks primed for a breakout soon. Business update Nov 6. Late Breaking data poster Nov7 & oral presentation Nov11 @ AASLD nov 8-11. Obesity phase 3 ready. MASH resolution & fibrosis improvement best in class at 24 weeks once FDA accepts NITs any day. 48wk top line NITs & end of phase 2 FDA meeting minutes also anyday! Renewed bidding wars between pfizer and Novo for a phase 1 obesity asset the same day Lilly announced their glp1 is the best selling drug in the world.   GS has been suppressing this SP indiscriminately to protect the market for their customers NOVO & LILly. A huge risk reward value only days away from business updates AND key oral presentation at THE liver conference of the year. Now is the time to load up! The price has been pinned for months abd the short interest is 25.5%.    This drug pemvutide is next generation. Better quality weight loss than good diet and exercise(21% lean muscle loss vs 24% typical diet & exercise), great tolerability due to proprietary euport technology, 74 % liver fat reduction. 6% weight loss at 24 weeks. Its a healthy new liver for all drinkers with a side of weight loss.   The next generation GLP1 at $4.  Your damn right im holding!   Who doesn't love an underdog story right before their breakout 

---

If we are comparing it to a phase 3 bio trial… Thats like saying Eli Lilly, Pfizer, and Merck are all supporting and collaborating on a drug that they have already proven has 100% efficacy yet just needs the production methods to monetize.

---